Tianze Jiao

Tianze Jiao, Ph.D.

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-9933
Business Email: tianzejiao@ufl.edu

About Tianze Jiao

Dr. Jiao accomplished his postdoctoral training at McGill University. Prior to it, he received his Ph.D. in Pharmacotherapy Outcomes Research & Health Policy from the University of Utah. He recently joined the Department of Pharmaceutical Outcomes & Policy as an Assistant Professor.

His research focuses on investigating and applying innovative and rigorous epidemiologic, economic, and comparative effectiveness research methods to identify and apply the precision medicine approach that will result in optimal outcomes for each patient in a resource-efficient manner. His goal is to investigate precision medicine that is both applicable for specific diseases and affordable, through the use of advanced study design (i.e. adaptive treatment strategy), cutting-edge statistical methods, and machine learning approaches adopting longitudinal Big Data. He has experience in multiple therapeutic areas with a focus on cardiology and pulmonology. As a principal investigator, currently, he is investigating the personalized optimal target blood pressure for patients with the hypertension-a project that is funded by the Canadian Institutes of Health Research.

Keywords: Pharmacoepidemiology, Big Data, Adaptive treatment strategy, Machine learning, Cardiology, Pulmonology

Teaching Profile

Courses Taught
2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2023-2024
PHA6910 Supervised Research
2023-2024
PHA5223 P-Epidem Drug Safety
2023
PHA6938 Research Seminar

Publications

2023
5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Diabetes, obesity & metabolism. [DOI] 10.1111/dom.15332. [PMID] 37867175.
2023
Letter by Jiao and Ruzieh Regarding Article, “Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex”.
Circulation. 148(6):508-509 [DOI] 10.1161/CIRCULATIONAHA.123.064702. [PMID] 37549202.
2023
Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood-Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals With Hypertension at High Cardiovascular Risk.
American journal of epidemiology. 192(9):1576-1591 [DOI] 10.1093/aje/kwad091. [PMID] 37073411.
2022
Identifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model.
Respiratory medicine. 198 [DOI] 10.1016/j.rmed.2022.106866. [PMID] 35594754.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare.
Diabetes care. 45(8):1814-1821 [DOI] 10.2337/dc21-2601. [PMID] 35700384.
2021
Predictors of Asthma Control and Exacerbations: A Real-World Study.
The journal of allergy and clinical immunology. In practice. 9(7):2802-2811.e2 [DOI] 10.1016/j.jaip.2021.04.049. [PMID] 33962067.
2021
Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom.
American journal of hypertension. [DOI] 10.1093/ajh/hpab137. [PMID] 34448818.
2014
Real-world evidence in pain research: a review of data sources.
Journal of pain & palliative care pharmacotherapy. 28(3):294-304 [DOI] 10.3109/15360288.2014.941131. [PMID] 25136897.
2013
Application of electronic medical record data for health outcomes research: a review of recent literature.
Expert review of pharmacoeconomics & outcomes research. 13(2):191-200 [DOI] 10.1586/erp.13.7. [PMID] 23570430.
2013
Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.
Journal of managed care pharmacy : JMCP. 19(9):789-98 [PMID] 24156648.
2012
A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Journal of pain & palliative care pharmacotherapy. 26(2):153-64 [DOI] 10.3109/15360288.2012.671240. [PMID] 22509775.

Grants

Dec 2022 ACTIVE
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention
Role: Co-Investigator
Funding: EMORY UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2022 ACTIVE
Characterizing efficacy and safety of hormonal contraceptives by combining pharmacometrics and RWE
Role: Principal Investigator
Funding: BILL & MELINDA GATES FOUNDATION

Contact Details

Phones:
Business:
(352) 273-9933
Emails:
Business:
tianzejiao@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610